Avinger (NASDAQ: AVGR) stock was up 47% yesterday followed by another 28% post market. AVGR stock was thus up 88% on the whole day, although this was a significant fallback from the peak rise of near 300%. We’d suggest that peak showed a great deal too much hope in the announcement. Whether that presages a fall back from current levels will be a matter of opinion.
The basics - Avinger is a microcap pharma device manufacturer which has just announced the market arrival of its latest equipment. As a background: “Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company’s lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, including Ocelot and Tigereye, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients.” OK, useful stuff in modern medicine.
The announcement: “....today announced full commercial launch of its Tigereye ST next generation image-guided chronic total occlusion (CTO) crossing system. With the initiation of full commercial launch, all current and prospective accounts can now order the Tigereye ST device.” And we can see the attraction, coming out of development and fully launching.

Avinger stock price from Google Finance
Whether putting a product on the market is quite worth 88% on the stock price is another matter - it clearly wasn’t worth the near 300% it reached at one point. We can conclude that there’s been more than a little momentum trading here. We could also note that market capitalisation - at the start of this - was under $3 million, so small changes in prospects could have large changes in valuation.
We would also note that they’ve cash at the last reporting date of near $8 million, which provides them with 6 months at their current burn rate. We think it’s most unlikely that product revenues are going to arrive quickly enough to change that calculation - selling significant medical devices is not a swift process, nor is collecting the cash for them. So, we expect this bounce in the stock price to be met with some stock issuance soon enough. Sensible management would wait until the product is market launched before asking for more capital after all.
We therefore expect there to be a cap on possible Avinger stock price rises - that likely soon to arrive stock issuance.



